Adjuvants, AnesthesiaPhase 2/3NCT03021772
Neostigmine Versus Dexamethasone as Adjuvants to Lidocaine During Intravenous Local Anesthesia
A Phase 2/3 study testing Neostigmine and Dexamethasone in people with Adjuvants, Anesthesia, run by Assiut University at 1 site in Egypt.
Trial summary
Intravenous regional anesthesia (IVRA) is described firstly in 1908 by August Bier. It is simple, safe, reliable, less cost, efficient method in forearm surgery. The advantage of this method has fast return of motor and sensory function which enables patients for earlier discharge. Read more about this study
- Who is it for?
- Ages 20 to 60 years
- Conditions the study is for
- Adjuvants, Anesthesia
- What is being tested?
- Neostigmine and Dexamethasone
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- Jan 2017to 30 Sep 2018
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age from 20 - 60 years.
- ASA grade I - II.
- Surgical time does not exceed 90 minutes.
Who cannot join
- Patient refusal.
- Any contraindication of regional anesthesia block (e.g. Coagulopathy, infection at the needle insertion site or vascular insufficiency).
- A personal history of seizures, peripheral neurologic diseases, cardiac arrhythmias, sickle cell anemia, liver dis¬ease, renal dysfunction and cardiac conduction abnormalities.
- Patients with allergy to amide local anesthetics or medication included in the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Efficacy of Neostigmine Versus Dexamethasone as Adjuvants to Lidocaine During Intravenous Local Anesthesia for Forearm Orthopedic Surgeries
Intravenous regional anesthesia (IVRA) is described firstly in 1908 by August Bier. It is simple, safe, reliable, less cost, efficient method in forearm surgery. The advantage of this method has fast return of motor and sensory function which enables patients for earlier discharge. However, this method has disadvantages such as tourniquet pain, insufficient muscle relaxation and postoperative analgesia.
Lidocaine inhibits action potential propagation within neuronal tissue by binding to receptors in Na+ channels located on the nerve cell membrane. Lidocaine IVRA is safe and effective and is associated with a rapid onset (4.5 minutes) of anesthesia after injection and termination of analgesia (5.8 ± 0.5 minutes) once the tourniquet is deflated.
Read more
Neostigmine is a typical cholinesterase inhibitor. It increases the level of acetylcholine (Ach) and indirectly stimulates both nicotinic and muscarinic receptors. In anesthesia, neostigmine is a drug that has been used for reversal of residual neuromuscular block. Administration of neostigmine by intrathecal and epidural routes has been found to cause analgesia by inhibition of the breakdown of Ach in the spinal cord.
Dexamethasone is commonly used in anesthesia to prevent postoperative nausea and vomiting (PONV). Two recent meta-analyses have documented that dexamethasone also reduced postoperative pain and opioid requirement. Intravenous dexamethasone has also been shown to improve postoperative pain control in patients receiving spinal or epidural morphine.
Hong et al reported that intravenous dexamethasone in combination with a caudal block with ropivacaine prolonged the duration of postoperative analgesia without adverse effects in children undergoing orchidopexy. So the investigators expect that addition of dexamethasone or neostigmine will affect duration and postoperative analgesia in bier block.
Read the detailed description
This study will be a prospective clinical randomized controlled double-blind study using a computer-generated randomization. Neither the doctor "investigator" nor the participant "patient" will be aware of the group allocation or the drug used. The study drugs will be prepared by one of the supervisor anesthesiologists (not included in the procedure, observation or data collection).
The study will be carried out in Assiut University Hospital after approval from our local ethical committee.
Patients
The patients will be classified in two groups:
According to sample size calculator. Group D: will include 30 patients and will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for bier block.
Group N: will include 30 patients and will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for bier block.
Methods
Before the procedure, the patient should be:
- Starved for 6-8 hours.
- Monitored closely (standard monitoring applied: HR, NIBP, SaO2 and RR)
- Adequately informed about the procedure and have consented to it.
The equipments required for IVRA include:
- Pneumatic tourniquet (checked for leaks before the procedure) and a pressure gauge.
- Esmarch bandage or Rhys-Davis exsanguination.
- Local anesthetic solution and the adjuvants.
- Resuscitation equipments and drugs.
Technique:
IVRA of the arm: a 22 G cannula is placed intravenously as distal as possible in the arm to be anesthetized. Venous access is established in the opposite arm to allow administration of fluids or other drugs if necessary. The double tourniquet (two tourniquets each 6 cm wide) or a single one (14 cm wide) is applied on the operated arm with generous layers of padding, ensuring that no wrinkles are formed and the tourniquet edges do not touch the skin.
The arm is exsanguinated either by using the Esmarch bandage or a Rhys-Davis exsanguinator. If this is impossible, exsanguination can be achieved by elevating the arm for 2-3 minutes while compressing the axillary artery. The distal tourniquet is inflated to at least 100 mm Hg higher than the patient's systolic blood pressure (250 - 300 mmHg). The proximal tourniquet is inflated to the same pressure.
After ensuring inflation, the distal cuff is deflated. Before injecting local anesthetic, it must be confirmed that no radial pulse is palpable. The local anesthetic is then injected slowly. A standard volume for injection into the upper limb is 40 ml, which can be increased to 50 ml in a fit, large adult.
If the injection is too rapid, the venous pressure may exceed the tourniquet pressure and the local anesthetic solution may escape into the systemic circulation. Surgical anesthesia is usually achieved within 15 minutes. The distal tourniquet, which overlies part of the anesthetized arm, can then be inflated and the proximal one deflated to relieve tourniquet pain. The cuff should not be deflated until 20 minutes after local anesthetic injection because systemic toxic doses of local anesthetic may occur.
Cuff deflation should be performed in cycles with deflation/inflation times of less than 10 seconds until the patient no longer exhibits signs of systemic toxicity (e.g. tingling of the lips, tinnitus or drowsiness). Therefore, the patient should be monitored closely for 30 minutes following tourniquet release. So, the investigators expect that addition of dexamethasone or neostigmine will affect duration and postoperative analgesia.
Data collection:
- Patient's data: include patient's gender, age, weight, height, BMI and ASA classification.
- Preoperative data:
- Basic Monitoring: heart rate (HR), non-invasive blood pressure (NIBP), arterial oxygen saturation (SaO2), respiratory rate (RR) will be recorded.
- Preoperative investigations: prothrombin time, prothrombin concentration and INR to avoid any risk of internal bleeding.
- Basal assessment of motor power and sensation of the limb:
<!-- -->
- Motor power: Motor block was evaluated by thumb abduction (radial nerve), thumb adduction (ulnar nerve), thumb opposition (median nerve), and flexion at the elbow (musculocutaneous nerve) on a 3-point scale for motor function (0: normal motor function, 1: reduced motor strength but able to move fingers, 2: complete motor block).
- Sensation: Sensory block (4 nerves) was assessed by ice packs using a 3-point scale: 0: normal sensation, 1: loss of sensation of cold (analgesia), 2: loss of sensation of touch (anesthesia). d- The standard value of visual analogue scale will be set as the score during passive exercise before the surgery.
- Introperative data:
- Basic Monitoring: heart rate (HR), non-invasive blood pressure (NIBP), arterial oxygen saturation (SaO2), respiratory rate (RR) will be recorded every 10 minutes till the end of surgery.
- Sensory and motor block: Sensory and motor blocks will be evaluated every 5 minutes until 20 minutes after injection. Onset time will be defined as the time interval between the end of total local anesthetic administration and complete sensory block. Complete sensory block will be defined by anesthetic block (score 2) on all nerve territories. Complete motor block will be defined as absence of voluntary movement on hand and forearm (score 0). c- Duration of surgery.
- Postoperative data:
- Duration of sensory and motor block: Duration of sensory block will be defined as the time interval between the end of local anesthetic administration and the complete resolution of anesthesia on all nerves. Duration of motor block will be defined as the time interval between the end of local anesthetic administration and the recovery of complete motor function of the hand and forearm.
- Duration of analgesia: interval between onsets of the block to the time of the first analgesic requirement.
- Analgesia assessment: Postoperatively, a Post-Anesthesia Care Unit (PACU) nurse will assess the quality of analgesia. The pain score will be recorded using the Visual Analouge Scale (VAS) 2, 4, 6, 12 and 24 hours after surgery. Significant pain is defined as one that has a score of ≥ 4 and as a consequence required a supplementary dose of analgesia. Intravenous Paracetamol 15 mg/kg, will be administered and recorded. d- Documentation of any complications: Includes local anesthetic toxicity \& drug additives complications. Local anesthetic toxicity:
- Initial symptoms are subjective and include perioral tingling or numbness, lightheadedness, tinnitus, metallic taste, slurred speech, auditory and visual disturbances.
- Minor symptoms usually do not require treatment. If any of these occur observe patient closely and identify any potential reasons for systemic toxicity eg: check for cuff failure - re-inflate.
- Significant neurotoxicity: Objective signs are usually excitatory: twitching, fasciculation and seizures:
- Check for cuff failure - re-inflate immediately
- Administer Midazolam 2.5-5.0 mg iv
- Support the ABC's as indicated Most seizures are self-limiting but can be potentiated by hypoxia, acidosis and hypercarbia so these should be treated aggressively.
- Significant cardiotoxicity: if occurs (eg: hypotension, bradycardia and arrhythmias): Give oxygen and adopt an ACLS approach Check for cuff failure - re-inflate immediately Bicarbonate may be indicated to address acidaemia. Drug additives complications: All patients will be monitored for any complications that may occur from any adjuvant drugs used in the study and will be treated promptly. Statistical analysis All data will be collected and analyzed using SPSS version 20 (SPSS, Inc., Chicago, Illinios, USA). Normally distributed data will be expressed as mean ± standard deviation, range, numbers and percentages. A probability (p) value of less than 0.05 will be considered statistically significant.
- Conditions
- Adjuvants, Anesthesia
- Being tested
- Neostigmine, Dexamethasone
- Keywords
- Neostigmine, Dexamethasone, Intravenous Local Anesthesia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NeostigmineDrug
Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
DexamethasoneDrug
Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
| Study group | Role | What they receive |
|---|---|---|
| Group N | Active comparator | 30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block. Receives: Drug: Neostigmine |
| Group D | Active comparator | 30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block. Receives: Drug: Dexamethasone |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain assessed on VAS
perfalgan will be given when visual analogue score ≥ 4
Measured: 24 hours
Secondary outcomes (3)
Sensory level
duration of sensory block
Measured: 2 hours
Motor level
duration of motor block
Measured: 2 hours
Number of patients with any complications
Percentage of patients with any complications will be recorded
Measured: 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2017 (estimated)
- Study startJan 2017
- Primary completion30 Sep 2018
- Study completion30 Sep 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adjuvants, AnesthesiaStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, MOHAMED F. MOSTAFA, Assiut University
- Investigators
- HAMDY A. YOUSSEF, MD, Study chair, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03021772
- Sponsor's protocol ID
- Bier Block
- Status last verified
- Jan 2019
- First submitted
- 10 Jan 2017
- Last updated
- 23 Jan 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Neostigmine Versus Dexamethasone as Adjuvants to Lidocaine During Intravenous Local Anesthesia for Forearm Orthopedic Surgeries
- ClinicalTrials.gov ID
- NCT03021772
- Acronym / sponsor ID
- Bier Block
- Conditions
- Adjuvants, Anesthesia
- Keywords
- Neostigmine, Dexamethasone, Intravenous Local Anesthesia
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Jan 2017 (actual)
- Primary completion
- 30 Sep 2018 (actual)
- Study completion
- 30 Sep 2018 (actual)
- First posted
- 16 Jan 2017 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Intravenous regional anesthesia (IVRA) is described firstly in 1908 by August Bier. It is simple, safe, reliable, less cost, efficient method in forearm surgery. The advantage of this method has fast return of motor and sensory function which enables patients for earlier discharge. However, this method has disadvantages such as tourniquet pain, insufficient muscle relaxation and postoperative analgesia.
Lidocaine inhibits action potential propagation within neuronal tissue by binding to receptors in Na+ channels located on the nerve cell membrane. Lidocaine IVRA is safe and effective and is associated with a rapid onset (4.5 minutes) of anesthesia after injection and termination of analgesia (5.8 ± 0.5 minutes) once the tourniquet is deflated.
Neostigmine is a typical cholinesterase inhibitor. It increases the level of acetylcholine (Ach) and indirectly stimulates both nicotinic and muscarinic receptors. In anesthesia, neostigmine is a drug that has been used for reversal of residual neuromuscular block. Administration of neostigmine by intrathecal and epidural routes has been found to cause analgesia by inhibition of the breakdown of Ach in the spinal cord.
Dexamethasone is commonly used in anesthesia to prevent postoperative nausea and vomiting (PONV). Two recent meta-analyses have documented that dexamethasone also reduced postoperative pain and opioid requirement. Intravenous dexamethasone has also been shown to improve postoperative pain control in patients receiving spinal or epidural morphine.
Hong et al reported that intravenous dexamethasone in combination with a caudal block with ropivacaine prolonged the duration of postoperative analgesia without adverse effects in children undergoing orchidopexy. So the investigators expect that addition of dexamethasone or neostigmine will affect duration and postoperative analgesia in bier block.
Detailed description
This study will be a prospective clinical randomized controlled double-blind study using a computer-generated randomization. Neither the doctor "investigator" nor the participant "patient" will be aware of the group allocation or the drug used. The study drugs will be prepared by one of the supervisor anesthesiologists (not included in the procedure, observation or data collection).
The study will be carried out in Assiut University Hospital after approval from our local ethical committee.
Patients
The patients will be classified in two groups:
According to sample size calculator. Group D: will include 30 patients and will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for bier block.
Group N: will include 30 patients and will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for bier block.
Methods
Before the procedure, the patient should be:
- Starved for 6-8 hours.
- Monitored closely (standard monitoring applied: HR, NIBP, SaO2 and RR)
- Adequately informed about the procedure and have consented to it.
The equipments required for IVRA include:
- Pneumatic tourniquet (checked for leaks before the procedure) and a pressure gauge.
- Esmarch bandage or Rhys-Davis exsanguination.
- Local anesthetic solution and the adjuvants.
- Resuscitation equipments and drugs.
Technique:
IVRA of the arm: a 22 G cannula is placed intravenously as distal as possible in the arm to be anesthetized. Venous access is established in the opposite arm to allow administration of fluids or other drugs if necessary. The double tourniquet (two tourniquets each 6 cm wide) or a single one (14 cm wide) is applied on the operated arm with generous layers of padding, ensuring that no wrinkles are formed and the tourniquet edges do not touch the skin.
The arm is exsanguinated either by using the Esmarch bandage or a Rhys-Davis exsanguinator. If this is impossible, exsanguination can be achieved by elevating the arm for 2-3 minutes while compressing the axillary artery. The distal tourniquet is inflated to at least 100 mm Hg higher than the patient's systolic blood pressure (250 - 300 mmHg). The proximal tourniquet is inflated to the same pressure.
After ensuring inflation, the distal cuff is deflated. Before injecting local anesthetic, it must be confirmed that no radial pulse is palpable. The local anesthetic is then injected slowly. A standard volume for injection into the upper limb is 40 ml, which can be increased to 50 ml in a fit, large adult.
If the injection is too rapid, the venous pressure may exceed the tourniquet pressure and the local anesthetic solution may escape into the systemic circulation. Surgical anesthesia is usually achieved within 15 minutes. The distal tourniquet, which overlies part of the anesthetized arm, can then be inflated and the proximal one deflated to relieve tourniquet pain. The cuff should not be deflated until 20 minutes after local anesthetic injection because systemic toxic doses of local anesthetic may occur.
Cuff deflation should be performed in cycles with deflation/inflation times of less than 10 seconds until the patient no longer exhibits signs of systemic toxicity (e.g. tingling of the lips, tinnitus or drowsiness). Therefore, the patient should be monitored closely for 30 minutes following tourniquet release. So, the investigators expect that addition of dexamethasone or neostigmine will affect duration and postoperative analgesia.
Data collection:
- Patient's data: include patient's gender, age, weight, height, BMI and ASA classification.
- Preoperative data:
- Basic Monitoring: heart rate (HR), non-invasive blood pressure (NIBP), arterial oxygen saturation (SaO2), respiratory rate (RR) will be recorded.
- Preoperative investigations: prothrombin time, prothrombin concentration and INR to avoid any risk of internal bleeding.
- Basal assessment of motor power and sensation of the limb:
<!-- -->
- Motor power: Motor block was evaluated by thumb abduction (radial nerve), thumb adduction (ulnar nerve), thumb opposition (median nerve), and flexion at the elbow (musculocutaneous nerve) on a 3-point scale for motor function (0: normal motor function, 1: reduced motor strength but able to move fingers, 2: complete motor block).
- Sensation: Sensory block (4 nerves) was assessed by ice packs using a 3-point scale: 0: normal sensation, 1: loss of sensation of cold (analgesia), 2: loss of sensation of touch (anesthesia). d- The standard value of visual analogue scale will be set as the score during passive exercise before the surgery.
- Introperative data:
- Basic Monitoring: heart rate (HR), non-invasive blood pressure (NIBP), arterial oxygen saturation (SaO2), respiratory rate (RR) will be recorded every 10 minutes till the end of surgery.
- Sensory and motor block: Sensory and motor blocks will be evaluated every 5 minutes until 20 minutes after injection. Onset time will be defined as the time interval between the end of total local anesthetic administration and complete sensory block. Complete sensory block will be defined by anesthetic block (score 2) on all nerve territories. Complete motor block will be defined as absence of voluntary movement on hand and forearm (score 0). c- Duration of surgery.
- Postoperative data:
- Duration of sensory and motor block: Duration of sensory block will be defined as the time interval between the end of local anesthetic administration and the complete resolution of anesthesia on all nerves. Duration of motor block will be defined as the time interval between the end of local anesthetic administration and the recovery of complete motor function of the hand and forearm.
- Duration of analgesia: interval between onsets of the block to the time of the first analgesic requirement.
- Analgesia assessment: Postoperatively, a Post-Anesthesia Care Unit (PACU) nurse will assess the quality of analgesia. The pain score will be recorded using the Visual Analouge Scale (VAS) 2, 4, 6, 12 and 24 hours after surgery. Significant pain is defined as one that has a score of ≥ 4 and as a consequence required a supplementary dose of analgesia. Intravenous Paracetamol 15 mg/kg, will be administered and recorded. d- Documentation of any complications: Includes local anesthetic toxicity \& drug additives complications. Local anesthetic toxicity:
- Initial symptoms are subjective and include perioral tingling or numbness, lightheadedness, tinnitus, metallic taste, slurred speech, auditory and visual disturbances.
- Minor symptoms usually do not require treatment. If any of these occur observe patient closely and identify any potential reasons for systemic toxicity eg: check for cuff failure - re-inflate.
- Significant neurotoxicity: Objective signs are usually excitatory: twitching, fasciculation and seizures:
- Check for cuff failure - re-inflate immediately
- Administer Midazolam 2.5-5.0 mg iv
- Support the ABC's as indicated Most seizures are self-limiting but can be potentiated by hypoxia, acidosis and hypercarbia so these should be treated aggressively.
- Significant cardiotoxicity: if occurs (eg: hypotension, bradycardia and arrhythmias): Give oxygen and adopt an ACLS approach Check for cuff failure - re-inflate immediately Bicarbonate may be indicated to address acidaemia. Drug additives complications: All patients will be monitored for any complications that may occur from any adjuvant drugs used in the study and will be treated promptly. Statistical analysis All data will be collected and analyzed using SPSS version 20 (SPSS, Inc., Chicago, Illinios, USA). Normally distributed data will be expressed as mean ± standard deviation, range, numbers and percentages. A probability (p) value of less than 0.05 will be considered statistically significant.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group N | Active comparator | Drug: Neostigmine30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block. |
| Group D | Active comparator | Drug: Dexamethasone30 patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block. |
Who may qualify
- Ages
- 20 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Age from 20 - 60 years.
- ASA grade I - II.
- Surgical time does not exceed 90 minutes.
Key exclusion criteria (4 listed)
- Patient refusal.
- Any contraindication of regional anesthesia block (e.g. Coagulopathy, infection at the needle insertion site or vascular insufficiency).
- A personal history of seizures, peripheral neurologic diseases, cardiac arrhythmias, sickle cell anemia, liver dis¬ease, renal dysfunction and cardiac conduction abnormalities.
- Patients with allergy to amide local anesthetics or medication included in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NeostigminePatients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block. | Drug | Group N |
| DexamethasonePatients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block. | Drug | Group D |
Primary outcome
Pain assessed on VAS
Time frame: 24 hours
perfalgan will be given when visual analogue score ≥ 4
3 secondary outcomes
Sensory level
Time frame: 2 hours
Motor level
Time frame: 2 hours
Number of patients with any complications
Time frame: 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2019.
- Individual participant dataSharing planned: Undecided
Related trials for Adjuvants, Anesthesia
Recruiting
Exploration of Appropriate BIS Range and Propofol Effect-site Concentration During Total Intravenous Anesthesia With Concomitant Adjuvants.
Knee Osteoarthritis, Replacement, Knee
Not yet recruitingPhase 3
Safety and Efficacy of Dexamethasone Versus Dexmedetomidine as Adjuvants in PENG Block in Hip Surgeries for Postoperative Pain Management
Postoperative Pain, Total Hip Arthroplasty (THA)
Not yet recruitingPhase 4
Ultrasound-Guided Ilioinguinal-Iliohypogastric Nerve Block Following Spinal Anesthesia Comparing Dexmedetomidine Versus Nalbuphine as Adjuvants to Bupivacaine in Unilateral Inguinal Hernia Repair
Inguinal Hernia, Postoperative Pain
Not yet recruitingPhase 2/3
Comparison of Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine in Ultrasound-Guided Erector Spinae Plane Block for Acute Pain Management in Patients With Traumatic Rib Fractures
Rib Fractures, Acute Pain
Enrolling by invitation
The Impact of Saline Temperature and Local Anesthetic Adjuvants on Postoperative Shoulder Pain and Inflammatory Marker Levels Following Laparoscopic Cholecystectomy
Shoulder Pain , Laparoscopic Cholecystectomy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
HAMDY A. YOUSSEF, MD study chair
Assiut University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Neostigmine and Dexamethasone in people with Adjuvants, Anesthesia, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain assessed on VAS (time frame: 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2019.